Moreover, treatment of fibroblasts from FRDA patients with DMF was shown to increase FXN mRNA levels (Jasoliya et al., 2019), but treatment with Omav or idebenone had no effect on FXN gene expression (Petrillo et al., 2019). The gene discussed is FXN; the disease is Friedreich ataxia.